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Abstract
Neonatal Abstinence Syndrome (NAS) is a condition in which an infant experiences
withdrawal from uterine exposure to various substances such as caffeine, nicotine,
amphetamines, THC, opioids, benzodiazepines, and other types of substances. Depending on the
severity of the symptoms, these infants may experience a longer hospital stay and may need
treatment and monitoring in the neonatal intensive care unit (NICU), resulting in an increase in
healthcare costs. The objective of this project was to determine if targeted drug screening of
newborns was effective in determining infants at risk of NAS based on a positive screening
result. This study utilized a retrospective, cross-sectional electronic health record (EHR) review
of infants born between September 1st, 2015 and September 1st, 2016 who met criteria for
umbilical cord drug screening. Rates of umbilical cord drug screening and screening results were
compared to risk factors associated with targeted drug screening criteria to determine which risk
factor criteria were predictive of a positive umbilical cord drug screening result. The EHR
records of 340 infants met criteria. Risk factors associated with targeted drug screening criteria
were not significantly sensitive nor specific in predicting infants at risk of NAS based on positive
drug screen results. In order to truly identify all infants at risk for withdrawal, universal
screening is recommended.
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Neonatal Abstinence Syndrome: Is Targeted Umbilical Cord Drug Screening Effective in
Determining Risk of Withdrawal?

Background
Neonatal Abstinence Syndrome (NAS) is a growing health problem in the United
States. “Between 2004 and 2014, the incidence of NAS in the United States increased from 1.5
per 1000 hospital births to 8.0 per 1000 hospital births, a more than fivefold increase”
(Winkelman, Villapiano, Kozhimannil, Davis, & Patrick, 2018). NAS is a condition in which an
infant experiences withdrawal from uterine exposure to various substances such as caffeine,
nicotine, amphetamines, THC, opioids, benzodiazepines, and other types of substances.
Depending on the severity of the symptoms, these infants may experience a longer hospital stay
and may require treatment and monitoring in the neonatal intensive care unit (NICU), resulting
in an increase in healthcare costs. When comparing healthcare costs from 2004 to 2014 of infants
with NAS covered by Medicaid, there was an annual increase in cost from $65.4 million in 2004
to $462 million in 2014. Over this ten-year period, there was over $2 billion in additional costs
for infants with a NAS diagnosis (Winkelman et al., 2018). NAS can lead to withdrawal
symptoms within the first 12-72 hours of life that include central nervous system (CNS)
disturbances, vasomotor dysregulation, gastrointestinal disturbances, and hyperirritability such as
tremors, fever, tachypnea, excoriation, diaphoresis, high-pitched crying, lack of sleep, vomiting,
diarrhea, and more severe symptoms such as seizures and respiratory distress (American College
of Obstetricians and Gynecologist, 2017; McQueen & Murphy-Oikonen, 2016; Timpson,
Killoran, Maranda, Picarillo, & Bloch-Salisbury, 2018). There are also long-term effects from
NAS. Infants who developed NAS were at an increased risk for problems with their vision,
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behavior, cognition, sleep, and ear infections as they matured (Maguire et al., 2016). There is
also a strong association between substance abuse disorder and child maltreatment, with 40-56%
of parents having abused or neglected their child when using substances (Maguire et al., 2016).
In a study described by Maguire et al. (2016), the incidence of child abuse was doubled when a
parent had a substance use disorder. NAS is a condition which not only affects an infant at birth,
but also throughout their lifetime as these problems continue to develop.
Determination of risk for NAS can be evaluated in a number of ways in regard to drug
screening mothers and/or infants (Terplan & Minkoff, 2017). Drug screening can be performed
on maternal or infant blood, urine, or hair as well as infant meconium, umbilical cord, or
placenta (McQueen & Murphy-Oikonen, 2016; Price, Collier, & Wright, 2018). Screening can
be selective, where drug testing is performed only if certain criteria are met. This may include
validated questionnaires provided to the mother or may be based on admission of a history of
substance use or abuse, placental abruption, precipitous labor, limited or no prenatal care, or
behavior suggestive of substance use in the mother or withdrawal in the infant. Drug screening
can also be universal, where all mothers or infants are chosen for drug screening. According to
Terplan and Minkoff (2017), selective drug screening is more cost-effective because it allows the
physician to narrow down those mothers who are at greatest risk of substance abuse, which
improves efficiency and specificity. However, the disadvantage with selective drug screening is
the decision to test may be based on bias or judgment and mothers and infants can be missed. In
a study described by Terplan and Minkoff (2017), black women and poor women were more
likely than others to be reported to social services, and infants of black women were more likely
to be drug screened. “Universal testing avoids the risk of implicit bias and has the advantage of
simplicity” (Terplan & Minkoff, 2017, p. 165). This also avoids relying on a woman’s honesty in
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her substance abuse history to decide whether an infant is screened and monitored for
withdrawal. Often, women are scared to admit information about their drug use history due to
fear of being reported to social services or having legal action taken against them (Truog, 2015).
In the state of Kentucky, where this research was conducted, the incidence of NAS has
increased thirty-sevenfold from 2000-2013, with 0.4 cases per 1000 live births in 2000 and 15.0
cases per 1000 live births in 2013 (National Institute on Drug Abuse, 2018). When looking at the
incidence of NAS across the 28 states included in an analysis by the National Institute on Drug
Abuse (2018), the overall United States average was 6.0 cases per 1000 live births. In an analysis
by the Kentucky Department for Public Health (2016), the most common substances used by
mothers during pregnancy were buprenorphine (58.4%), other opiates (35.2%), THC (22.8%),
heroin (20.4%), amphetamines (14.4%), and benzodiazepines (14.2%). In this same report, the
Kentucky Department for Public Health (2016) stated that outcomes for NAS included child
fatalities due to unsafe sleep habits as well as nonaccidental head trauma. “Because babies with
NAS can have irritability and feeding problems for months after discharge, they are likely to be
at higher risk for these deaths” (Kentucky Department for Public Health, 2016, p. 11). With the
continued rise in NAS diagnoses due to substance abuse in pregnancy in the United States and
especially the commonwealth of Kentucky, it is imperative that a plan be made to identify which
infants are most at risk of withdrawal.
The goal of targeted drug screening of newborns is to identify newborns at risk of NAS
by using risk factors often associated with maternal substance use. Early identification of infants
at greatest risk of NAS can help determine infants who would benefit from early
intervention/treatment. The objective of this project was to determine if targeted drug screening
of newborns was effective in determining infants at risk of NAS. An additional aim was to
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compare Finnegan scores of infants who were positive to those who were negative to determine
the significance of Finnegan scoring in assessing signs of withdrawal. This project sought to
compare positive drug screening results to the associated selective drug screening criteria in
order to determine which screening criteria were most predictive of a positive result.
Theoretical Framework
The theoretical framework chosen for this project was the John Hopkins Nursing
Evidence-Based Practice (JHNEBP) Model, which uses a three-step process to provide and apply
the latest and best research to nursing practice and patient care (John Hopkins University &
Medicine, 2020). The three steps in this process are called PET: practice question, evidence, and
translation. The first step in this model is presenting a practice question. The purpose of the
practice question is to present the problem and find a focused and specific question that can
guide what kind of study or evidence is needed to move forward. For this project, the practice
question was: What is the best way to identify which infants are at risk of NAS? The next step in
the JHNEBP Model is to search for the evidence and resources that can answer the practice
question. By doing a thorough literature review, gaps in literature can be found and the practice
question can be shaped to find the best type of study that is needed. For this project, the literature
review revealed gaps in the research comparing targeted screening protocols to universal
screening protocols at the same facility as well as identifying which targeted drug screening
criteria were the most accurate in determining a positive result. The last step in the JHNEBP
Model is translation, which uses the practice question and literature review to decide on what
type of study to perform (John Hopkins University & Medicine, 2020). For this project, there
were two different pathways to take when considering the practice question. When considering
the gap in literature where targeted screening and universal screening had not been performed
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and compared at the same facility, the first translation was to do a prospective study. This study
would have consisted of implementing a universal screening protocol at a facility that already did
risk-based screening, and then comparing the additional infants that were found to be at risk of
NAS. The second translation was to perform a retrospective medical record review where riskbased criteria were compared to the number of positive results in order to determine the
sensitivity of risk-based screening. Due to the limitations in funding for universal screening and
the need for informed consent from every parent, a retrospective literature review was chosen to
determine the efficacy of a targeted screening protocol. The JHNEBP Model provided a straight
forward straightforward approach to identifying the best study for this practice question and
ensured that the latest research would be used to support this project (John Hopkins University &
Medicine, 2020).
Review of Literature
The studies included in this literature review demonstrated a variety of information
supporting the use of umbilical cord drug screening and early identification of infant’s at risk of
withdrawal. One study utilized a systemic literature review, ten studies utilized a cohort analysis,
one utilized a comparison study, one a cross-sectional study, and three studies utilized a survey
(see Appendix A). Of the sixteen studies retrieved for this review, five examined hospital
practices and protocols regarding drug-screening criteria and efficacy of drug testing (Bogen et
al., 2017; Miller et al., 2014; Murphy-Oikonen et al., 2010; Wexelblatt et al., 2015; Wood et al.,
2017), four examined whether umbilical cord screening and meconium screening was equivalent
(Colby, 2017; Colby et al., 2019; Labardee et al., 2017; Palmer et al., 2017), and four examined
the prevalence of maternal substance abuse (Buchi et al., 2013; Kreshak et al., 2016; Lange et al.,
2016; Schauberger et al., 2014). Of the remaining studies, two examined the maternal risk factors
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associated with the highest prevalence of positive drug screenings (Son et al., 2018; Wood et al.,
2014), and one study examined the effects of race on maternal targeted screening (Ellsworth et
al., 2010).
Most of the studies described the problem of increased substance abuse in pregnancy and
the importance of proper screening to identify infants at-risk of withdrawal. Of those studies that
compared hospital protocols and policies regarding maternal and infant drug screening,
researchers found that a larger percentage of hospitals performed targeted screening as opposed
to universal screening. Bogen et al. (2017) found that 90% of 76 hospitals from 34 states used
risk-based screening compared to 3% that used universal screening. Miller et al. (2014) found
that among 31 Maryland hospitals, 48% used targeted screening compared to 45% who used
universal screening. Wood et al. (2017) found that in 69 Iowa hospitals, 90% used targeted
screening and 0% used universal screening. Studies described maternal risk factors associated
with targeted drug screening and included criteria such as a positive history of maternal drug
screening at delivery or during pregnancy, a history of substance use disorder before pregnancy,
limited or no prenatal care, maternal legal involvement, prior Child Protective Services (CPS)
involvement, other offspring not in custody, placental abruption, preterm labor, maternal tobacco
or alcohol use, HIV positive status, HbsAg positive status, Hepatitis C positive status, history of
gonorrhea or syphilis, fetal demise, precipitous delivery, intra-uterine growth restriction (IUGR),
unintended delivery outside of the hospital, and acting intoxicated during office visits or on
admission to the hospital (Bogen et al., 2017; Buchi et al., 2013; Colby, 2017; Ellsworth et al.,
2010; Fonti et al., 2016; Miller et al., 2014; Murphy-Oikonen et al., 2010, Son et al., 2018;
Wexelblatt et al., 2015, Wood et al., 2014). Although screening by risk factors can reduce cost,
bias has been found to exist in how providers determine who should be screened. A study by
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Ellsworth et al. (2010) identified 565 mothers that met criteria for targeted screening protocols,
but only 20.7% of these women were actually screened. Of those screened appropriately, infants
born to black mothers were three times more likely to be screened compared to white mothers. In
assessing infants of mothers who did not meet any criteria for screening, infants of black mothers
were four times more likely to be screened not having any risk factors.
Researchers found that maternal drug testing not only revealed substance use during
pregnancy, but showed women were not always honest in their self-reports of substance use due
to fear of discrimination and legal retribution. Risk factors alone did not always determine
whether a woman would have a positive result. When studying the prevalence of substance use
by pregnant women in the office setting, Kreshak et al. (2016) and Schauberger et al. (2014)
found that 13-30% of women tested positive for one or more substances in urine samples. Of
those samples found to be positive, marijuana and opioids had the highest prevalence. Three
studies examined the difference in maternal self-reports and risk factors in comparison to
universal infant drug screening results (Lange et al., 2014; Murphy-Oikonen et al., 2010;
Wexelblatt et al., 2015). Lange et al. (2014) found that detection of alcohol in meconium
samples was four times higher than what was admitted in maternal self-reports, Murphy-Oikonen
et al. (2010) found that mothers failed to admit drug use in 27% of positive urine samples and
24% of positive meconium samples, Wexelblatt et al. (2015) found that 20% of opioid-positive
urine drug screenings of infants occurred in mothers without standard risk factors.
Of the four studies that examined the equivalence of meconium drug screening to
umbilical cord screening, only one study found that umbilical cord screening was not as sensitive
as meconium screening. Colby (2017) studied 217 subjects and found that 45 samples had a
positive result in meconium and not umbilical cord and 17 samples had a positive result in
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umbilical cord and not meconium. It was determined by this study that umbilical cord had a
lower sensitivity but had >90% specificity in all but one drug class. Colby et al. (2019) used a
sample of 501 infants and found that umbilical cord was more sensitive to amphetamines,
barbiturates, and benzodiazepines than meconium and determined that umbilical cord and
meconium was discordant. Labardee et al. (2017) studied 197 specimens and found that nine
oxycodone and eight opiate results were found in meconium but not detected in umbilical cord
and two methamphetamine results were found in umbilical cord but not detected in meconium.
This study expressed the benefit of umbilical cord collection to nursing workflow and timing of
collection. Meconium may take 24 hours or more for the infant to pass and collect, while
umbilical cord is available immediately after delivery. This allows an easier collection by the
nurse, less chance of missing a sample and allows the sample to be sent to the laboratory sooner.
Palmer et al. (2017) sampled 2072 infants and found that umbilical cord and meconium testing
did not differ significantly, and umbilical cord testing was better because it decreased missed
collections, increased detection of iatrogenic medications provided during labor, decreased
tampering of the sample, and eliminated insufficient sample volume.
Agency Description
This project took place on the Birthplace unit of Hardin Memorial Hospital in
Elizabethtown, Ky. Hardin Memorial Hospital is a 300-bed hospital in Central Kentucky that
includes six labor and delivery suites, fourteen postpartum couplet rooms, a newborn nursery,
and a level II NICU with seven beds (Hardin Memorial Health, 2019). The Birthplace unit,
which includes all these areas, is the ninth busiest newborn delivery unit in Kentucky and
includes over 1,600 annual live births. The population of this study was all infants born between
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September 1, 2015 and September 1, 2016 at Hardin Memorial Hospital who underwent
umbilical cord drug screening as a result of a targeted drug screening policy.
“The mission of Hardin Memorial Health is to exceed the physical, emotional, and
spiritual needs of our patients, their families, our physicians, and our staff through the delivery of
high-quality, comprehensive care to the people and communities we serve” (Hardin Memorial
Health, 2019, para. 4). The vision of this organization is to be the leading choice of residents
who live within the community as a result of relentless quality improvement. Hardin Memorial
Hospital values the ability to succeed in this mission as well as be guided by this vision as a way
to achieve respect, integrity, collaboration, excellence, and stewardship (Hardin Memorial
Health, 2019). This DNP project supported the mission and vision of the organization by seeking
to improve patient outcomes and quality of care in the newborn. With the only level II NICU in
Central Kentucky, the main objective of this project was to assess the efficacy of a current
targeted drug screening policy in order to better identify those infants who may be at-risk of
NAS.
The key stakeholders included the national, state, and local governments, behavioral
health professionals, hospital social workers, child protective services (CPS), OB/GYNs,
pediatricians, neonatologists, nurses, laboratories, and leadership. Government agencies use the
project data to update information on NAS prevalence and recommendations for screening across
the United States. Behavioral health professionals and social workers at the hospital offer
resources and treatment to the mother. The social workers and CPS work together on each case
where there is a positive screening result to assess the need for custody changes, home visits, or
follow-up after discharge. OB/GYNs, pediatricians, neonatologists, and nurses are stakeholders
related to their direct care of these patients. OB/GYNs provide information on maternal risk
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factors and are updated on any positive results found so that they can provide appropriate care to
the mother. Neonatologists and pediatricians screen, treat, and follow up with these infants. The
laboratories are kept up to date on the timing and specificity and sensitivity of the results. Lastly,
the project findings inform leadership about the need for permanent policy changes as well as to
share this research with other delivery hospitals in order to provide recommendations for infant
screening.
The largest facilitator to the implementation of this project was the ease of access to the
data, since this was a medical record review. The policy that this project was evaluating was one
that was already in place and was being followed by the providers and nursing staff. There was
no education or training needed and no informed consent needed, only approval through the
research committee within the hospital and the IRB. Another facilitator was the support from
leadership, providers, and nursing staff in making this project a success and determining which
targeted screening criteria was the most accurate in identifying at-risk infants.
The largest barrier to this project was availability of resources at this facility for a formal
research project such as this. Although this hospital has a research committee, this often consists
of quality improvement initiatives and does not include formal research where IRB approval is
needed. Due to this, there were limited people within the facility who understood how the
process worked or what steps were required to move forward. Many meetings had to be
scheduled and questions asked from several leadership individuals to find out what was needed
to advance this project forward. Another barrier to this project was the ability of IT to run the
report that specifically isolated the population chosen. When having IT run the requested reports,
this either included all infants born within this time period or a select number of infants that had
samples missing. This created a lengthy process of reviewing every infant record over the one-
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year period to make sure no data was missed. Also, drug screen results had to be scanned into the
medical record during the years chosen for this review, rather than being uploaded electronically,
so some of the results were not readily available. Until the time when the result was
automatically loaded into the medical record, many of the drug screening results had to be found
through the umbilical cord drug screening laboratory.
Project Design
This project was a cross-sectional medical record review. This study involved collecting
data on all infants born between September 1st, 2015 and September 1st, 2016 who met criteria
for umbilical cord drug screening based on targeted screening criteria. This criteria included the
following maternal risk factors: history of or current drug use, minimal prenatal care, precipitous
labor, severe mood swings, unexplained sores on skin, abruptio placentae, inappropriate
behavior, myocardial infarction, poor dentition, unexplained fetal demise, cerebrovascular
accidents, late prenatal care, no prenatal care, repeated spontaneous abortions, or unexplained
severe hypertension. These criteria also included the following infant risk factors: myocardial
infarction in a healthy term newborn, urogenital anomalies, abnormal neurological behaviors,
necrotizing enterocolitis in a healthy term newborn, cardiovascular accident in a healthy term
newborn, or unexplained intrauterine growth restriction (IUGR), pediatrician (MD) order,
preterm less than 36 weeks, and a prior history with CPS (see Appendix B). The following
demographics were collected on each infant: gender, race/ethnicity, age of mother, and gestation
at birth. The following admission, assessment, and discharge information was collected on each
infant: need for NICU admission for NAS treatment with morphine therapy, average Finnegan
score, highest Finnegan score, and length of stay. The following outcomes were measured for
each infant: individual targeted screening criteria met for mother, individual targeted screening
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met for infant, and the result of the drug screen (see Appendix C). Nominal data included the
gender of the infant, the race of the infant, the infant and maternal drug screening criteria met,
the result of the drug screening, and whether the infant was admitted to the NICU for treatment.
Ordinal data included the gestation of the infant, length of stay, the highest Finnegan score, and
the average Finnegan score. Interval data included the age of the mother. The population was
found by having IT run a report on all infants born between these dates that had Finnegan
scoring performed as well as all infants born within these dates that had an umbilical cord sent
for drug screening. Data for this study was accessed using the electronic health record (EHR).
Data analysis was quantitative and included frequency distributions for nominal data, and the
means, standard deviations, and ranges for continuous variables. SPSS analysis was used to run a
two-sample t-test to determine the significance of Finnegan scoring, and sensitivity and
specificity was used to compare the number of positive and negative results to each risk factor.
Project Methods
The method used for this study was a retrospective cross-sectional design that compared
umbilical cord drug screening rates and results to risk factors associated with targeted drug
screening criteria in order to determine which risk factors were the best predictor of a positive
umbilical cord drug screening result. In order to measure this, the sensitivity and specificity were
calculated for each of the risk factors (Table 3). In addition, the average and highest Finnegan
scores were compared using a two-sample t-test to assess whether the difference in scores were
significant when comparing those of a positive drug screen to those of a negative drug screen
(Table 4). The mean, median, standard deviation, and ranges were collected for all continuous
variables and the frequency and percentages were collected for each nominal variable (Tables 1
and 2).
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Procedures
IRB Approval
An IRB application was submitted to the University of Kentucky’s IRB as well as Baptist
Health Lexington’s IRB. Baptist Health Lexington is the IRB required for studies taking place at
Hardin Memorial Hospital. Both applications were approved in September 2019.
Sample
The sample size included 340 infants that met criteria for drug screening for one or more
reasons listed in Appendix B. The positivity report listed in Table 5 shows that 341 umbilical
cords were tested during the chosen timeframe, but only 340 infants were used for the sample
size after performing the medical record review. The sample included all infants born between
September 1st, 2015 to September 1st, 2016 who underwent umbilical cord drug screening as a
result of the targeted drug screening policy. Infants born prior to September 1st, 2015 and after
September 1st, 2016 and those infants that did not meet umbilical cord drug screening criteria
were excluded from this study.
Measures and Instruments
A medical record review was performed to collect the data on the sample and all
information was found in the electronic health records of the infants. The nominal data collected
included the gender of each infant, the race of each infant, whether the infant was admitted to the
NICU for NAS treatment (i.e. morphine therapy), the results of the drug screening and whether
the infant did or did not meet criteria for the following risk factors: history of drug use, minimal
prenatal care, late prenatal care, no prenatal care, precipitous labor, severe mood swings,
unexplained sores on skin, abruptio placentae, inappropriate behavior, myocardial infarction,
poor dentition, unexplained fetal demise, cerebrovascular accident, repeated spontaneous
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abortions, unexplained severe hypertension, myocardial infarction in healthy term newborn,
urogenital anomalies, abnormal neuro behaviors, necrotizing enterocolitis in healthy term
newborn, cardiovascular accident in health term newborn, unexplained intrauterine growth
restriction (IUGR), preterm less than 36 weeks, previous history of CPS, and pediatrician (MD)
order. The continuous variables measured were maternal age, gestation of the infant at birth,
length of hospital stay, highest Finnegan score, and average Finnegan score (Appendix C).
Implementation
In order to implement this project, a medical record review was performed. Since this
project was a retrospective study that included a medical record review only, a waiver of
informed consent was approved by the IRB.
Results
The average maternal age for the 340 infants chosen for this project was 26 years old (SD
= 5.71) and the average gestation at birth was 38.1 weeks (SD = 2.60). The mean for the average
Finnegan score was 1.2 (SD = 1.39) and the mean for the highest Finnegan score was 3.5 (SD =
3.23). The average length of stay for infants was 3.79 days (SD = 5.55), and the median number
of days was 2 days (Table 1). The difference between the mean and median for length of stay is
inconsistent with short stays for most infants, with longer stays for a small subset. If an infant
was preterm or required morphine therapy in the NICU, the length of stay was as high as 50
days. The median was chosen to provide a better reflection of the number of days most infants
stayed in the hospital, as a least half of the infants stayed for two or fewer days.
The sample had a total of 164 (48.2%) males and 176 (51.8%) females. There was a total
of 263 (77.6%) Caucasian infants, 55 (16.2%) African American infants, 15 (4.4%) Hispanic
infants, 1 (0.3%) Native American infant, and 5 (1.5%) infants listed as “other”. Of the 340
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infants in the sample, seven (2.1%) required morphine therapy for withdrawal treatment and
were admitted to the NICU. When treating infants with morphine in the NICU for high Finnegan
scores, the infant or mother must have tested positive for opiates. Out of the 341 umbilical cord
samples reported in the positivity report, 40 (11.7%) were positive for opiates (Table 5). When
considering that only opiate withdrawal infants received morphine therapy for NAS symptoms, a
total of 17.5% of opiate-positive infants required treatment with morphine.
A total of 77 (22.6%) infants tested positive for the following substances: amphetamines,
cocaine, opiates, cannabinoids, methadone, and benzodiazepines (Table 5). The maternal and
infant risk factors used to drug screen all infants at this facility (Appendix B) showed 113
(33.2%) mothers had a history of drug use (Table 2). Nearly 28% of the mothers had either
minimal, late, or no prenatal care prior to delivery. Precipitous labor, placental abruption, and
recurrent spontaneous abortions were noted criteria in 18.8% of the births. Inappropriate
behavior or severe mood swings were identified as screening criteria in 5.6% of those who were
tested. One in ten had poor maternal dentition or unexplained sores on the skin as criteria for
screening. Infant findings were listed as criteria in 8.8% of those who were tested. Five percent
of infants were drug screened based on a pediatrician or neonatologist order. Several of the
criteria used for targeted screening were not found with any of those who were screened. Those
risk factors not identified were maternal myocardial infarction, unexplained fetal demise,
maternal cerebrovascular accident, unexplained severe maternal hypertension, myocardial
infarction in a healthy term newborn, necrotizing enterocolitis in a healthy term newborn, and
cerebrovascular accident in a healthy term newborn.
Based on the number of risk factors found in the medical record, 16 (4.7%) infants had no
risk factors, 275 (80.9%) infants had one risk factor, 43 (12.6%) had two identified risk factors,
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and 6 (1.8%) infants had three risk factors present. A total of 291 (85.6%) infants had zero to one
risk factors and 49 (14.4%) infants had more than one risk factor.
Two-sample t-tests were used to compare the average Finnegan scores and the highest
Finnegan scores between those infants that tested positive and those that tested negative (Table
4). The mean average Finnegan score for those infants that tested positive was 1.5 and the mean
average Finnegan score for those that tested negative was 1.1. Based on the two-sample t-test
performed, it was found that the difference in these averages was statistically significant. The
mean highest Finnegan score for those infants that tested positive was 4.46 and the mean highest
Finnegan score for those that tested negative was 3.22. Based on the two-sample t-test
performed, it was found that the difference in the highest Finnegan scores was statistically
significant (Table 4).
In the context of risk factor assessment, sensitivity is the percentage of women with a
positive drug screen who were also positive for the corresponding risk factor. On the other hand,
specificity is the percent of those with a negative drug screen who were also negative for the
presence of the given risk factor. The risk factor with the highest sensitivity was maternal history
of drug use, with a sensitivity of 51.9 (specificity 72.7) (Table 3). Minimal prenatal care had a
sensitivity of 14.3 (specificity 85.9), late prenatal care had a sensitivity of 13.0 (specificity 87.8),
precipitous labor had a sensitivity of 10.4 (specificity 90.8), poor dentition had a sensitivity of
10.4 (specificity 89.4), and the remaining risk factors had sensitivities of less than 10%. The
highest specificity was 100, which was found with cardiovascular accident in the mother and
healthy term newborn, necrotizing enterocolitis in healthy term newborn, myocardial infarction
in the mother and healthy term newborn, unexplained fetal demise, and maternal cerebrovascular
accident; the sensitivity for all these risk factors was zero, as none of the mothers had any of
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these risk factors. Given the number of possible risk factors, it was also considered that those
infants with positive drug screens were more likely to have more than one risk factor. The
sensitivity of having more than one risk factor was 20.8 and the specificity was 87.5 (Table 3).
Discussion
The sensitivity of a screening test is the ability of a test to detect a true positive. It is the
probability that someone with a positive drug screen will be flagged as high-risk using a given
risk factor. When a test has a high sensitivity, there are very few false negative results (Maxim,
Niebo, & Utell, 2014). The specificity of a screening test is the ability of a test to detect a true
negative. It is the probability that those infants not exposed to drugs in utero will be negative on
the identified risk factor as well. When a test has a high specificity, there are very few false
positive results (Maxim et al., 2014). The best test would be one with 100% sensitivity and
specificity because this would result in no error in the outcome, but this is not achievable in
practice. Therefore, the most desirable test is one that has both high sensitivity and high
specificity (Maxim et al., 2014).
When considering the risk factors used to screen infants for NAS, the highest sensitivity
was 51.9% for history of drug use. Using the presence of having two or more risk factors as an
evaluation tool was associated with only 20.8% sensitivity. The remainder of the risk factors
were less than 15% sensitive. This sensitivity is far from 100% and is very low, which means
there is a much higher risk of false negatives. In this context, a false negative would be a
participant who had a positive drug screen but who was not positive for a given risk factor. The
values for the specificities were much higher, with 20 out of the 24 risk factors being above 90%.
Infants with multiple risk factors had a specificity of 87.5%. The lowest specificity was 72.7%
for history of drug use, which means there is a relatively low risk of false positives with all of
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these risk factors. A false positive in this study would have occurred if a participant had a
negative drug screen but was positive for a particular risk factor.
In using these data to identify whether risk factors are effective in evaluating risk of
withdrawal, none of the risk factors were very sensitive in indicating positive drug screening
results. In order to truly assess the number of positive results that are being missed, universal
screening would have to be performed and compared between those who met risk factor
screening and those who did not. Although it is more expensive to test every infant, it would
allow a better determination of whether risk factors are efficient in finding all those infants at
risk of NAS. It would also identify those risk factors most strongly linked to NAS outcomes.
Another comparison considered differences in Finnegan scores between positive drug
screening and negative drug screening. The Finnegan scoring tool is the most commonly used
scoring system for evaluating infants with NAS (Pomar et al., 2017). Developed in 1975, it
consists of 21 scored items or symptoms involving the central nervous system, the autonomic
nervous system, and the gastrointestinal system. Higher scores are consistent with NAS
(Appendix D). The recommendation for practice with the Finnegan tool is to consider further
monitoring and initiation of pharmacological treatment if the infant has three consecutive scores
of eight or more or two consecutive scores of 12 or more (Pomar et al., 2017).
While performing the medical record review, it was noted that many infants with
negative drug screens had high Finnegan scores. This could have been due to the infant
withdrawing from other medications not tested on the 9-panel drug screen ordered for these
screenings or it may have been due to the subjective nature of Finnegan scoring and the various
people scoring the infant throughout the hospitalization. In performing a two-sample t-test on the
average Finnegan scores and the highest Finnegan scores, it was found that the average Finnegan
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score and highest Finnegan scores were significantly higher for the positive result group relative
to those whose drug screens were negative. This suggests that, on average, there is a significant
association between Finnegan scoring and drug screen results, even though some in the negative
group had relatively high scores and some in the positive group had relatively low ones.
Implications for Practice, Education, Policy, and Future Research
This project was started with advocating for universal drug screening. Due to the cost
associated with screening all infants, the first step was proving that risk-based screening is not
effective. By assessing the sensitivity and specificity of each risk factor, it was shown that these
criteria are not very effective at determining those infants at risk of NAS. As stated in the
literature review, risk-based screening may be based on bias or judgment and mothers are not
always honest in their history (Terplan and Minkoff, 2017). This leads to infants being
discharged without being screened for withdrawal symptoms, where they may reach the peak of
withdrawal at home. By providing universal screening, there is a standardized process and no
infant is missed and sent home without help.
Another area for improvement with NAS is increasing the hospital length of stay.
Although infant’s met criteria for drug screening and the umbilical cord samples had not yet
resulted, most infants were discharged after two days of birth. Most substances have a
withdrawal onset of 24-72 hours and a total duration in the body of 2-30 days (Kocherlakota,
2014). It is important to keep infants for the most appropriate amount of time to properly assess
their readiness for discharge. While performing the medical record review, there were many
infants that had high Finnegan scores throughout the hospital stay and were still discharged at
two days of life. In a management plan recommended by Kocherlakota (2014), Finnegan scoring
should begin within 24 hours of birth and occur every 3-4 hours. If scores remain consistently at
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or below eight, the infant should continue to be observed for 3-5 more days before being
discharged.
The current policy at this facility states that infants who are exposed to opiates should be
monitored for 4-5 days for signs of withdrawal. The hospital cost per day at this facility is
$1054.00 for those infants outside of the NICU. With 252 infants being discharged at or before 2
days of life (n=340), this would have resulted in an increase in cost of $265,608 - $796,824 if the
length of stay was extended to 3-5 days. Although this would result in an increase in healthcare
costs at this facility, this would decrease infant withdrawal at home and would allow social
services to get involved before an infant is discharged home with a parent that tested positive for
a substance. Not only would this prevent the negative physical effects of withdrawal but would
also prevent the infant from discharging home to an environment that could place the infant in
additional harm. If an infant presents to the hospital after discharge with severe NAS or
nonaccidental trauma due to the social environment, this would result in an increase in healthcare
costs overall as well as negative long term outcomes for the child. Since the umbilical cord
processing time can take 3-6 days after birth, it is important to consider each infant’s Finnegan
scores and the substances in which he or she is withdrawing from before deciding on a discharge
date.
The future of this research involves replicating this study at other facilities with other risk
factors to see if other criteria might be a better predictor of a positive drug screening. Each
facility differs in their criteria, and there might be better efficacy with other risk factors. The
current policy at this facility no longer includes infants less than 36 weeks and never included an
MD order or previous history with CPS, although this was noted in some of the medical records.
The sensitivity of preterm infants and MD order was 0% while history of CPS was 2.6%.
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Perhaps preterm infants should not automatically be screened, and the MD should communicate
other criteria for screening before placing this order. A previous history with CPS was found to
be a risk factor at other facilities when performing the literature review and, although it was not
very sensitive in this study, CPS often asks for a drug screening when reviewing these cases.
This might be a risk factor that this facility should consider adding. If other facilities can
replicate this research and find that their criteria are not very sensitive or specific, then universal
screening may be the next step.
The future of this research is to compare universal screening to risk-based screening in
order to determine how many infants are missed with risk-based screening alone. Although this
would result in higher drug screening costs, all infants would be screened and scored for NAS in
order to assess for signs of withdrawal and to provide treatment when necessary. By
standardizing the approach to infant drug screening, no infants at risk of NAS would be missed.
This would allow researchers to prove which type of screening is more effective and hospitals
could begin to either standardize the risk criteria used or could begin providing universal
screening.
Limitations
One limitation of this study is the small sample size. Some risk criteria were not
experienced by any participants in the study; a larger sample size would allow a better
quantification of the sensitivity and specificity of each risk factor. In addition, not all risk factors
were noted in the medical records of each infant. If a drug screening was performed after the
infant was born, this was often not noted in the chart as to why. Without documentation of why
an umbilical cord was sent for testing, there is no way to measure how effective the result was.
During the time frame chosen for this review, the hospital also utilized a 9-panel umbilical cord
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drug screening compared to the 13-panel drug screening used now. This could have resulted in
negative drug screening results for those infants that were actually positive for these additional
substances (oxycodone, meperidine, tramadol, and buprenorphine). Although the same infants
would have been tested based on the risk factors associated, this might have resulted in more
positive drug screenings. Some infants had multiple risk factors chosen, while others did not.
Another limitation is not knowing whether more than one risk factor was not chosen because the
infant did not have more than one risk factor or because only one option was chosen to trigger
the infant drug screening.
One of the greatest limitations to this study was the lack of funding to support universal
drug screening of all infants. Universal drug screening was supported by the pediatric and
leadership team of the department, but the resources were not available to support this increase in
drug screening cost. At this facility, the cost of a 13-panel umbilical cord drug screening is
$177.00. This cost is not billed to the patient, but is paid for by the hospital because this testing
is performed at another laboratory outside of the hospital’s network. With a hospital average of
1600 live births a year, this would result in over 1200 additional umbilical cord drug screenings.
The increase in this cost would be over $220,000. In order to properly identify all those potential
NAS infants that are being missed by risk-based screening, universal screening would need to be
implemented and compared to risk-based screening. Without the resources to fund this project,
there is no data to support the need for universal screening or the evidence to prove that it is
more efficient in finding all infants at risk of NAS.
Conclusion
Early identification of infants at greatest risk of NAS can help determine those who
would benefit from early intervention/treatment. The main goal of this project was to determine
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if risk-based screening was efficient in determining a positive drug screening result. Without
universal screening, more sensitive and specific risk-based screening is important in determining
which infants are at greatest risk and need additional monitoring to assess for signs of
withdrawal. Based on the statistical analysis, the risk factors associated with this project were not
sensitive in finding positive infants. Maternal history of drug use was the only risk factor that
had a high enough sensitivity to suggest significance. In order to be more efficient at scoring and
monitoring infants with NAS, there must be a better process in place for identifying those that
are at greatest risk. With more research on risk-based screening and more resources available to
implement and study universal screening, there will continue to be advancements in identifying
infants with NAS. With such significant side effects associated with withdrawal, it is important
that this research continue and that infants be protected from suffering. In addition,
understanding and identifying substance use in pregnancy can also provide more resources to the
mother for help and sobriety. NAS involves family-centered care for both the infant and the
mother, and proper screening is the first step in helping them in their journey to recovery.
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Appendix A – Literature Review
Type of Study

Number of Studies

Authors

Systemic Literature Review

1

Lange, Shield, Koren, Rehm, & Popova, 2014

Cohort Analysis

10

Colby, 2017; Colby, Adams, Morad, Presley, &
Patrick, 2019; Ellsworth, Stevens, & D’Angio, 2010;
Kreshak et al., 2016; Murphy-Oikonen, Montelpare,
Southon, Bertoldo, & Persichino, 2010; Palmer,
Wood, & Krasowski, 2017; Schauberger, Newbury,
Colburn, & Al-Hamadani, 2014; Son, Guiahi,
Heyborne, 2018; Wexelblatt et al., 2015; Wood et al.,
2014

Comparison Study

1

Labardee et al., 2017

Cross-sectional Study

1

Buchi, Suarez, & Varner, 2013

Survey

3

Bogen, Whalen, Kair, Vining, & King, 2017; Miller,
Lanham, Welsh, Ramanadhan, & Terplan, 2014;
Wood, Smith, & Krasowski, 2017
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Appendix B – Drug Screening Criteria
Targeted Drug Screening Criteria at Hardin Memorial Hospital
Maternal Considerations
History or Current Drug Abuse
Minimal Prenatal Care
Precipitous Labor
Severe Mood Swings
Unexplained Sores on Skin
Abruptio Placentae
Inappropriate Behavior
Myocardial Infarction
Poor Dentition
Unexplained Fetal Demise
Cerebrovascular Accidents
Late Prenatal Care
No Prenatal Care
Repeated Spontaneous Abortions
Unexplained Severe Hypertension

Infant Considerations
Myocardial Infarction in Healthy Term Newborn
Urogenital Anomalies
Abnormal Neuro Behaviors
Necrotizing Enterocolitis in Healthy Term Newborn
Cardiovascular Accident in Healthy Term Newborn
Unexplained Intrauterine Growth Restriction (IUGR)
Preterm Less than 36 Weeks
Pediatrician (MD) order
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Appendix C – Data Collection
Measures

Description

Level of Measurement

Data Source

Demographics
Gender of Infant

Male vs Female

Nominal

Race/Ethnicity of Infant

Nominal/Categorical

Maternal Age

Caucasian, African American,
Hispanic, Native American, Other
Age in years

Gestation

Gestation by weeks

Ordinal

Interval/Ratio

Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records

Admission, Assessment, and Discharge Information
Need for NICU admission

Nominal

Electronic Health
Records

Finnegan Score

Was infant admitted to the NICU
for NAS treatment (i.e. morphine
therapy)?
Highest Finnegan Score

Ordinal

Finnegan Score

Average Finnegan Score

Ordinal

Length of Stay for Infants

Average Length of Stay in Days

Ordinal

Electronic Health
Records
Electronic Health
Records
Electronic Health
Records

History of Drug Use

Yes/No

Nominal

Minimal Prenatal Care

Yes/No

Nominal

Late Prenatal Care

Yes/No

Nominal

No Prenatal Care

Yes/No

Nominal

Precipitous Labor

Yes/No

Nominal

Severe Mood Swings

Yes/No

Nominal

Unexplained Sores on Skin

Yes/No

Nominal

Abruptio Placentae

Yes/No

Nominal

Inappropriate Behavior

Yes/No

Nominal

Myocardial Infarction

Yes/No

Nominal

Poor Dentition

Yes/No

Nominal

Unexplained Fetal Demise

Yes/No

Nominal

Outcomes
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Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records

Cerebrovascular Accident

Yes/No

Nominal

Repeated Spontaneous Abortions

Yes/No

Nominal

Unexplained Severe Hypertension

Yes/No

Nominal

Myocardial Infarction in Healthy Term
Newborn
Urogenital Anomalies

Yes/No

Nominal

Yes/No

Nominal

Abnormal Neuro Behaviors

Yes/No

Nominal

Necrotizing Enterocolitis in Healthy
Term Newborn
Cardiovascular Accident in Healthy Term
Newborn
Unexplained Intrauterine Growth
Restriction (IUGR)
Preterm Less than 36 Weeks

Yes/No

Nominal

Yes/No

Nominal

Yes/No

Nominal

Yes/No

Nominal

Previous History with CPS

Yes/No

Nominal

Pediatrician (MD) Order

Yes/No

Nominal

Result of Drug Screen

Positive/Negative

Nominal
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Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Records
Electronic Health
Record

Appendix D – Finnegan Scoring

Hudak et al. (2012)
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Table 1. Means, medians, standard deviations and ranges for selected continuous variables: (N =340).
Variable
Mean
Median
Standard
Actual Range
Deviation
Maternal Age
5.71
15 – 44
26.07
25.00
2.60
20.1 – 42.0
Gestation at Birth
38.14
39.00
Average Finnegan Score
1.39
0 – 9.43
1.20
0.75
Highest Finnegan Score
3.23
0 – 17
3.50
3.00
Length of Hospital Stay
3.79
2.00
5.55
0 – 50
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Table 2. Frequency distributions for selected categorical variables (N=340)
Variable

Frequency

Gender
Male
Female
Race
Caucasian
African American
Hispanic
Native American
Other
Need for NICU Admission for NAS Treatment?
Yes
No
Result of Drug Screen
Positive
Negative
History of Drug Use
Yes
No
Minimal Prenatal Care
Yes
No
Late Prenatal Care
Yes
No
No Prenatal Care
Yes
No
Precipitous Labor
Yes
No
Severe Mood Swings
Yes
No
Unexplained Sores on Skin
Yes
No
Abruptio Placentae
Yes
No
Inappropriate Behavior
Yes
No
Myocardial Infarction in Mother
Yes
No
Poor Dentition
Yes
No
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Percent (%)

164
176

48.2
51.8

263
55
15
1
5

77.6
16.2
4.4
0.3
1.5

7
333

2.1
97.9

77
263

22.6
77.4

113
227

33.2
66.8

48
292

14.1
85.9

42
298

12.4
87.6

4
336

1.2
98.8

32
307

9.4
90.6

2
338

0.6
99.4

7
333

2.1
97.9

9
331

2.6
97.4

17
323

5.0
95.0

0
340

0
100.0

36
304

10.6
89.4

Unexplained Fetal Demise
Yes
No
Cerebrovascular Accident in Mother
Yes
No
Repeated Spontaneous Abortions
Yes
No
Unexplained Severe Hypertension
Yes
No
Myocardial Infarction in Healthy Term Newborn
Yes
No
Urogenital Anomalies
Yes
No
Abnormal Neuro Behaviors
Yes
No
Necrotizing Enterocolitis in Health Term Newborn
Yes
No
Cerebrovascular Accident in Healthy Term Newborn
Yes
No
Unexplained Intrauterine Growth Restriction
Yes
No
Preterm Less than 36 Weeks
Yes
No
Pediatrician (MD) Order
Yes
No
Number of Risk Factors
0
1
2
3
Multiple Risk Factors
0-1
>1
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0
340

0
100.0

0
340

0
100.0

23
317

6.8
93.2

0
340

0
100.0

0
340

0
100.0

1
339

0.3
99.7

11
329

3.2
96.8

0
340

0
100.0

0
340

0
100.0

7
332

2.1
97.6

4
336

1.2
98.8

16
324

4.7
95.3

16
275
43
6

4.7
80.9
12.6
1.8

291
49

85.6
14.4

Table 3. Sensitivity and specificity for each risk factor relative to outcome of postnatal drug screen (N = 340).
Risk Factor in Mother
Sensitivity (%)
Specificity (%)
History of drug use

51.9

72.7

Minimal Prenatal Care

14.3

85.9

Late Prenatal Care

13.0

87.8

No Prenatal Care

2.6

99.2

Precipitous Labor

10.4

90.8

Severe Mood Swings

1.3

99.6

Unexplained Sores on Skin

0

97.3

Abruptio Placentae

1.3

97.0

Inappropriate Behavior

2.6

94.3

Myocardial Infarction in Mother

0

100.0

Poor Dentition

10.4

89.4

Unexplained Fetal Demise

0

100.0

Cerebrovascular Accident in Mother

0

100.0

Repeated Spontaneous Abortions

5.2

92.8

Unexplained Severe Hypertension

0

100.0

Risk Factor in Infant

Sensitivity (%)

Specificity (%)

Myocardial Infarction in Healthy Term Newborn

0

100.0

Urogenital Anomalies

0

99.6

Abnormal Neuro Behaviors

1.3

96.2

Necrotizing Enterocolitis in Health Term Newborn

0

100.0

Cardiovascular Accident in Healthy Term Newborn

0

100.0

Unexplained Intrauterine Growth Restriction

1.3

97.7

Preterm Less Than 36 Weeks

0.0

98.5

Previous History with CPS

2.6

98.1

Pediatrician (MD) Order

0.0

93.9

Multiple Risk Factors in Mother and/or Infant
>1 Risk Factors

Sensitivity (%)
20.8
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Specificity (%)
87.5

Table 4. Comparison of Average and Highest Finnegan Scores for Positive and Negative Drug Screening Results
Mean
Standard Deviation
|t|
p
Significant?
Average Finnegan Score
Negative Result
Positive Result
Highest Finnegan Score
Negative Result
Positive Result

1.1
1.5

1.27
1.70

2.0

.049

Yes

3.22
4.46

2.94
3.93

2.6

.012

Yes
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Table 5. Positivity report for umbilical cord drug screenings performed from 9/1/15 – 9/1/16.
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